AzTrials
AzTrials

Sensorineural Hearing LossEarly Phase 1HEAR-RESTORENCT07472023

Regenerative Medicine and Stem Cell-Based Interventions for Inner Ear Trauma, Tinnitus, and Sensorineural Hearing Loss

A Early Phase 1 study testing Audiologic Monitoring, Investigational Regenerative Pharmacologic Therapy and Stem Cell Regenerative Therapy in people with Sensorineural Hearing Loss and Tinnitus, run by Truway Health, Inc. at 1 site in United States.

Enrolling by invitation

Enrolling by invitation. The study team selects and invites participants, usually from an existing group of patients.

Sites and contacts
Official record
Search all trials

Trial summary

The HEAR-RESTORE study is an exploratory clinical research program designed to evaluate new diagnostic and regenerative approaches for individuals experiencing inner ear injury, tinnitus, and temporary or permanent hearing loss. Read more about this study

Who is it for?
Any age
What is being tested?
Audiologic Monitoring, Investigational Regenerative Pharmacologic Therapy and Stem Cell Regenerative Therapy
Could I receive a placebo?
No, everyone receives an active treatment
How many people
120 participants
Where
1 siteUnited States
Study dates
8 Mar 2026to 8 Mar 2099
Phase
Early Phase 1
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Adults aged 18-75 years
  • Clinical diagnosis of sensorineural hearing loss, tinnitus, or inner ear injury
  • Hearing threshold ≥25 dB HL at one or more audiometric frequencies
  • Ability to complete audiometric testing and follow study procedures
  • Ability to provide informed consent

Who cannot join

  • Active middle ear infection
  • History of cochlear implant surgery
  • Known retrocochlear pathology
  • Participation in experimental hearing regeneration therapy within 12 months
  • Known pregnancy at time of enrollment
  • Any medical condition that may interfere with study participation or safety

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

United States1 site
  • Truway Health, Inc. , View 34, 401 E 34th Street, S11P, New York, NY 10016

    New York, New York, 10016

Other trials in United States

About this study

Official title: Truway Health Inner Ear Regeneration & Hearing Restoration Trial

The HEAR-RESTORE study is an exploratory clinical research program designed to evaluate new diagnostic and regenerative approaches for individuals experiencing inner ear injury, tinnitus, and temporary or permanent hearing loss. Inner ear disorders can result from acoustic trauma, infections, inflammation, or other conditions that affect the cochlea, auditory nerve, or vestibular system. These conditions may lead to muffled hearing, ringing in the ears (tinnitus), balance disturbances, or reduced hearing sensitivity.

The purpose of this study is to better understand how inner ear injuries develop and to evaluate potential treatments that may support hearing recovery or protect auditory function. Participants will undergo comprehensive ear and hearing evaluations including audiometry, speech recognition testing, tympanometry, and other diagnostic assessments used in audiology and otolaryngology. These tests help measure hearing thresholds, ear pressure, and auditory nerve responses.

Read more

The study may also explore emerging regenerative medicine strategies aimed at restoring inner ear function. These approaches may include investigational therapies designed to promote repair of cochlear hair cells, reduce inflammation in the inner ear, or support neural recovery in the auditory pathway. Research may include evaluation of regenerative biological therapies, stem cell-based approaches, and other experimental technologies intended to support recovery of hearing or reduce symptoms such as tinnitus.

Participants will be monitored over time to assess hearing outcomes, safety, and changes in auditory function. Study assessments may include repeat audiology tests, imaging studies, symptom questionnaires, and other clinical measurements used to track hearing health.

The results of this research may contribute to improved diagnostic methods and potential future treatments for individuals with hearing loss or inner ear disorders.

Read the detailed description

Inner ear disorders are a major cause of hearing impairment worldwide and may result from a variety of causes including acoustic trauma, infections, inflammatory processes, vascular compromise, or degenerative conditions affecting the cochlea and auditory nerve. Damage to sensory hair cells within the cochlea is a common mechanism leading to sensorineural hearing loss and tinnitus. In many cases, these cells do not regenerate naturally in humans, resulting in persistent hearing impairment.

The HEAR-RESTORE study is a translational research program designed to investigate diagnostic, monitoring, and investigational therapeutic approaches for individuals experiencing inner ear injury, tinnitus, and temporary or permanent hearing loss. The study focuses on improving the understanding of cochlear injury mechanisms and evaluating potential regenerative and protective strategies that may support auditory recovery.

Participants enrolled in the study will undergo comprehensive otologic and audiologic evaluations. Baseline assessments will include a detailed clinical history, otoscopic examination, and standardized hearing tests. Audiologic evaluations will include pure-tone audiometry to determine hearing thresholds across multiple frequencies, speech recognition testing, tympanometry to evaluate middle ear pressure and compliance, and otoacoustic emissions testing to assess cochlear hair cell function. Additional neuro-auditory testing such as auditory brainstem response (ABR) testing may be performed to evaluate auditory nerve conduction and central auditory pathways.

The study may also include advanced diagnostic tools such as vestibular function testing, imaging studies of the inner ear structures, and digital symptom monitoring to assess tinnitus severity and functional hearing ability in daily environments. These assessments allow researchers to characterize patterns of hearing impairment and track changes over time.

In addition to diagnostic assessments, the study may explore investigational strategies aimed at supporting inner ear repair and auditory recovery. Research areas of interest include regenerative medicine approaches that aim to restore or protect cochlear hair cells and auditory neurons. Investigational concepts may include biological therapies designed to stimulate endogenous repair pathways, neuroprotective agents that reduce inflammatory damage in the cochlea, and emerging regenerative technologies intended to support cellular repair within the inner ear environment.

The research program may also investigate stem cell-based approaches and other regenerative biological strategies designed to promote repair of damaged auditory structures. These approaches are being explored in early-stage research as potential methods to support regeneration of cochlear hair cells or improve neural signaling in the auditory system. Any investigational therapies evaluated in this study will be assessed primarily for safety and feasibility, with careful monitoring of auditory outcomes and adverse events.

Participants may be followed longitudinally to evaluate hearing outcomes, symptom progression, and overall auditory function. Follow-up evaluations may include repeat audiometric testing, tinnitus symptom scoring, vestibular assessments, and patient-reported outcome measures. These data will allow researchers to evaluate whether investigational approaches are associated with improvements in hearing thresholds, speech recognition ability, or reductions in tinnitus severity.

The study will also collect observational data related to potential risk factors for inner ear injury, including noise exposure, environmental factors, medication history, and prior medical conditions that may affect auditory health. These data may help improve understanding of how hearing loss develops and identify populations that may benefit from early intervention.

The results of the HEAR-RESTORE study are expected to contribute to the development of improved diagnostic frameworks and future therapeutic strategies for individuals with inner ear disorders. By combining comprehensive audiologic evaluation with emerging regenerative research approaches, this program aims to advance scientific understanding of hearing restoration and support the development of new treatments for hearing loss and tinnitus.

The findings from this research may inform future clinical trials, guide development of regenerative therapies for the inner ear, and support improved clinical management of patients experiencing hearing impairment due to injury or disease affecting the auditory system.

Being tested
Audiologic Monitoring, Investigational Regenerative Pharmacologic Therapy, Stem Cell Regenerative Therapy, Combination Regenerative Therapy
Keywords
Hearing Loss, Inner Ear Regeneration, Cochlear Hair Cell Regeneration, Audiometry, Stem Cell Therapy, Regenerative Medicine, Tinnitus Treatment, Auditory Nerve Repair, Cochlear Injury, Hearing Restoration
Medical subject headings
Hearing Loss, Sensorineural, Tinnitus, Hearing Loss, Noise-Induced, Hearing Loss, Sudden, Hearing Loss

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Audiologic MonitoringOther

    Standard audiologic testing including pure-tone audiometry, speech recognition testing, tympanometry, and auditory function monitoring performed at scheduled study visits.

  • Investigational Regenerative Pharmacologic TherapyDrug

    Investigational pharmacologic agents designed to support inner ear repair or protect cochlear hair cells following injury.

  • Stem Cell Regenerative TherapyBiological

    Investigational regenerative therapy involving stem cell-based approaches intended to support repair of cochlear hair cells and auditory neural pathways.

  • Combination Regenerative TherapyCombination product

    Investigational combination therapy involving regenerative pharmacologic agents and biological therapies designed to promote recovery of auditory function.

Study groups in NCT07472023
Study groupRoleWhat they receive
Standard Audiologic MonitoringActive comparatorParticipants will undergo comprehensive audiologic evaluation and monitoring including pure-tone audiometry, speech recognition testing, tympanometry, and other standard diagnostic assessments used in otolaryngology. This arm serves as the standard-of-care comparison group for evaluating hearing outcomes.
Receives: Other: Audiologic Monitoring
Regenerative Pharmacologic TherapyExperimentalParticipants will receive investigational pharmacologic therapies designed to support inner ear recovery or protect cochlear hair cells following injury. Audiologic testing and symptom monitoring will be performed throughout the study period to evaluate hearing outcomes and safety.
Receives: Drug: Investigational Regenerative Pharmacologic Therapy
Stem Cell Investigational TherapyExperimentalParticipants will receive investigational regenerative medicine therapies involving stem cell-based approaches intended to support repair of inner ear structures or auditory nerve pathways. Audiometric and clinical monitoring will be conducted to evaluate safety and potential improvements in auditory function.
Receives: Biological: Stem Cell Regenerative Therapy
Combination Regenerative TherapyExperimentalParticipants will receive a combination of investigational regenerative strategies designed to support auditory recovery following inner ear injury. These approaches may include pharmacologic regenerative agents combined with biological or cellular therapies. Participants will undergo comprehensive hearing assessments throughout the study.
Receives: Combination Product: Combination Regenerative Therapy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in Pure-Tone Audiometry Hearing Threshold (dB HL)

    Change in hearing threshold levels measured in decibels hearing level (dB HL) across standard audiometric frequencies (0.25-8 kHz) using calibrated pure-tone audiometry. Lower dB HL values indicate improved auditory sensitivity.

    Measured: Baseline to 6 months

Secondary outcomes (3)
  1. Speech Recognition Score (Word Recognition Percentage)

    Speech recognition ability measured using standardized word recognition testing (e.g., NU-6 word lists). Scores range from 0-100%, with higher scores indicating better speech discrimination ability.

    Measured: Baseline to 6 months

  2. Change in Tinnitus Functional Index (TFI) Score

    Patient-reported tinnitus severity measured using the Tinnitus Functional Index (TFI). Scores range from 0-100, with higher scores indicating greater tinnitus severity. A decrease in score reflects clinical improvement.

    Measured: Baseline to 6 months

  3. Safety and Adverse Event Monitoring

    The incidence and severity of adverse events related to investigational interventions will be monitored throughout the study period. Safety outcomes will include clinical observations, audiologic findings, and any reported complications.

    Measured: Baseline through 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Mar 2026
  2. Study start8 Mar 2026
  3. Primary completion8 Mar 2097 (estimated)
  4. Study completion8 Mar 2099 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Participants will be assigned to parallel study arms evaluating diagnostic monitoring, regenerative medicine approaches, and investigational therapies designed to support recovery of inner ear function following injury or hearing loss. Outcomes will be compared across groups using standardized audiologic assessments.
Masking
None (open label)
Enrolment
120 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07472023
Sponsor's protocol ID
TH-PRS-IEAR-2026-001
Acronym
HEAR-RESTORE
Status last verified
Mar 2026
First submitted
8 Mar 2026
Last updated
16 Mar 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
Individual data sharing
Yes: De-identified individual participant data underlying the results reported in this study will be made available to qualified researchers following publication of the primary results. Data sharing will comply with applicable privacy protections, institutional policies, and regulatory requirements.

Publications

  • Shi F, Edge AS. Prospects for replacement of auditory neurons by stem cells. Hear Res. 2013 Mar;297:106-12. doi: 10.1016/j.heares.2013.01.017. Epub 2013 Jan 28.

    PubMed 23370457
  • Liberman MC. Noise-induced and age-related hearing loss: new perspectives and potential therapies. F1000Res. 2017 Jun 16;6:927. doi: 10.12688/f1000research.11310.1. eCollection 2017.

    PubMed 28690836
  • Brigande JV, Heller S. Quo vadis, hair cell regeneration? Nat Neurosci. 2009 Jun;12(6):679-85. doi: 10.1038/nn.2311. Epub 2009 May 26.

    PubMed 19471265

Questions about this trial

What is this clinical trial studying?

A Early Phase 1 study testing Audiologic Monitoring, Investigational Regenerative Pharmacologic Therapy and Stem Cell Regenerative Therapy in people with Sensorineural Hearing Loss and Tinnitus, run by Truway Health, Inc. at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: enrolling by invitation, as of the sponsor's last update on 16 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in Pure-Tone Audiometry Hearing Threshold (dB HL) (time frame: Baseline to 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07472023, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Mar 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in